目的：回顾性分析脑血疏口服液对高血压性脑出血患者脑内血肿吸收的影响。

方法：回顾性收集符合病例选择标准的84 例高血性压脑出血患者的病历资料，并将其分为脑血疏口服液组（41 例）和基础治疗组（43 例）。2 组患者均接受吸氧、止血、脱水降颅压、控制血压、基础疾病治疗和对症及支持治疗等，其中脑血疏口服液组患者在发病72 h 以内接受脑血疏口服液口服或经鼻饲给药，2 组患者均治疗10 d。治疗前及治疗10 d 后，采用计算机体层成像（computed tomography，CT）检查观察并计算脑内血肿体积，同时记录治疗期间脱水降颅压药物和降压药物的使用情况。

结果：2 组患者治疗前的性别、收缩压、舒张压和脑内血肿体积差异均无统计学意义（P ＞ 0.05），但年龄差异有统计学意义（P ＝ 0.005）。2 组患者治疗期间的脱水降颅压药物和降压药物使用率均无显著差异（P ＝ 0.529，P ＝ 0.898）；治疗10 d 后，2 组患者的脑内血肿体积均较治疗前缩小，但仅脑血疏口服液组患者的脑内血肿体积变化有统计学意义（P ＝ 0.001），且脑血疏口服液组患者治疗10 d 后的脑内血肿体积明显小于基础治疗组（P ＝ 0.046）。多重线性回归分析结果显示，年龄和血压与治疗前后脑内血肿体积及脑内血肿吸收量均无显著相关性（P ＞ 0.05）。

结论：脑血疏口服液治疗可缩小高血压性脑出血患者脑内血肿体积，促进脑内血肿吸收，而对脱水降颅压药物和降压药物的使用无明显影响。

Objective: To retrospectively analyze the effect of Nao-Xue-Shu Oral Liquid (NXS) on the absorption of intracerebral hematoma in patients with hypertensive intracerebral hemorrhage.

Methods: The medical records of eighty-four patients with hypertensive cerebral hemorrhage were retrospectively collected. The patients were divided into NXS group (n = 41) and basic treatment group (n = 43). Both groups received oxygen inhalation, hemostasis, dehydration, blood pressure control, basic disease treatment and symptomatic and supportive treatment. The patients in the NXS group received NXS orally or by nasal feeding within 72 hours since the disease onset. Both groups were treated for 10 days. Before treatment and 10 days after treatment, the volume of intracerebral hematoma was observed and calculated by computed tomography (CT), and the use of dehydration and antihypertensive drugs during treatment was recorded.

Results: There was no significant difference in gender, systolic blood pressure, diastolic blood pressure and intracerebral hematoma volume between the two groups before treatment (P > 0.05), but there was significant difference in age (P = 0.005). There was no significant difference in the use rate of dehydration and antihypertensive drugs between the two groups during treatment (P = 0.529, P = 0.898); after 10 days of treatment, the volumes of intracerebral hematoma of the two groups were smaller than those before treatment, but only the change of volume of intracerebral hematoma in the NXS group had statistical significance (P = 0.001). The volume of intracerebral hematoma in the NXS group after treatment for 10 d was significantly smaller than that in the basic treatment group (P = 0.046). Multiple linear regression analysis showed that age and blood pressure had no significant correlation with the volume of intracerebral hematoma before and after treatment and the absorption of intracerebral hematoma (P > 0.05).

Conclusion: NXS can reduce the intracerebral hematoma and promote the absorption of intracerebral hematoma in patients with hypertensive cerebral hemorrhage, but has no obvious effect on the use of dehydration and antihypertensive drugs.